Cardiac shock wave therapy for chronic refractory angina pectoris. a prospective placebo-controlled randomised trial
Cardiovascular Therapeutics, 04/25/2012Schmid JP et al.
This placebo controlled trial shows a significant improvement in symptoms, quality of life parameters and ischemic threshold during exercise in patients with chronic refractory angina pectoris treated with cardiac shock wave therapy (CSWT). Thus, CSWT represents a new option for the treatment of patients with refractory AP.
21 patients (mean age 68.2±8.3 years, 14 males) with chronic refractory angina pectoris and evidence of inducible myocardial ischemia during MIBI–SPECT imaging, were randomised into a treatment (n = 11) and a placebo arm (n = 10).
The region of exercise induced ischemia was treated with echocardiographic guidance during nine sessions over a period of 3 months.
One session of CSWT consisted of 200 shots/ spot with an energy intensity of 0.09 mJ/ mm2.
In the control group acoustic simulation was performed without energy application.
Medication was kept unchanged during the whole treatment period.
In the treatment group, symptoms improved in 9/11 patients, and the ischemic threshold, determined by cardiopulmonary exercise stress testing, increased from 80±28 to 95±28 W (p = 0.036).
In the placebo arm, only 2/10 patients reported an improvement and the ischemic threshold remained unchanged (98±23 to 107±23 W; p = 0.141).
The items “physical functioning” (p = 0.043), “general health perception” (p = 0.046) and “vitality” (p = 0.035) of the SF–36 questionnaire significantly improved in the treatment arm, whereas in the placebo arm, no significant change was noted.
Neither arrhythmias, troponin rise nor complications were observed during treatment.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.